Senomyx Releases Q1 Results

biotec1

Senomyx released their first quarter 2016 financial results, ending March 31, 2016. 

  • Commercial revenues $2.1 million against $657,000 in the first quarter of 2015.
  • Development revenues reached $4.2 million.
  • R&D, patent expenses and stock-based expenses decreased from $6.4 million to $5.4 million.
  • Selling, general and administrative expenses were $3.0 million.
  • Net loss for the quarter improved to $2.4 million from $4.6 million.

Moving forward, the company expects revenues to reach at least $6.1 million and for the net loss to not exceed $3.0 million in the second quarter of the year.

More in Flavor